Nicholas Investment Partners’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,218
| Closed | -$490K | – | 236 |
|
|
2024
Q4 | $490K | Sell |
1,218
-35
| -3% | -$16.2K | 0.04% | 210 |
|
|
2024
Q3 | $583K | Sell |
1,253
-4,383
| -78% | -$2.11M | 0.05% | 201 |
|
|
2024
Q2 | $2.64M | Buy |
5,636
+1,293
| +30% | +$561K | 0.27% | 126 |
|
|
2024
Q1 | $1.82M | Sell |
4,343
-3,479
| -44% | -$1.47M | 0.19% | 157 |
|
|
2023
Q4 | $3.18M | Sell |
7,822
-86,936
| -92% | -$32.1M | 0.37% | 106 |
|
|
2023
Q3 | $33M | Buy |
94,758
+14,642
| +18% | +$5.12M | 2.46% | 6 |
|
|
2023
Q2 | $28.2M | Sell |
80,116
-10,175
| -11% | -$3.43M | 1.93% | 15 |
|
|
2023
Q1 | $28.4M | Buy |
90,291
+42,050
| +87% | +$12.6M | 2.16% | 7 |
|
|
2022
Q4 | $13.9M | Sell |
48,241
-14,538
| -23% | -$4.43M | 1.22% | 29 |
|
|
2022
Q3 | $18.2M | Buy |
62,779
+710
| +1% | +$204K | 1.69% | 10 |
|
|
2022
Q2 | $17.5M | Hold |
62,069
| – | – | 1.65% | 12 |
|
|
2022
Q1 | $16.2M | Buy |
62,069
+23,782
| +62% | +$5.64M | 1.15% | 24 |
|
|
2021
Q4 | $8.41M | Buy |
+38,287
| New | +$7.45M | 0.53% | 71 |
|
|
2019
Q2 | – | Sell |
-14,214
| Closed | -$2.62M | – | 235 |
|
|
2019
Q1 | $2.62M | Buy |
14,214
+11,489
| +422% | +$2.12M | 0.23% | 146 |
|
|
2018
Q4 | $452K | Buy |
2,725
+149
| +6% | +$25.8K | 0.05% | 208 |
|
|
2018
Q3 | $496K | Buy |
+2,576
| New | +$459K | 0.04% | 211 |
|
|
2018
Q2 | – | Sell |
-32,709
| Closed | -$5.33M | – | 249 |
|
|
2018
Q1 | $5.33M | Buy |
32,709
+6,325
| +24% | +$1.03M | 0.38% | 75 |
|
|
2017
Q4 | $3.95M | Sell |
26,384
-13,667
| -34% | -$2.02M | 0.26% | 121 |
|
|
2017
Q3 | $6.09M | Buy |
40,051
+7,051
| +21% | +$1.06M | 0.42% | 63 |
|
|
2017
Q2 | $4.25M | Buy |
33,000
+214
| +0.7% | +$25.8K | 0.3% | 106 |
|
|
2017
Q1 | $3.58M | Buy |
+32,786
| New | +$2.89M | 0.25% | 141 |
|
|
2016
Q1 | – | Sell |
-27,115
| Closed | -$3.41M | – | 337 |
|
|
2015
Q4 | $3.41M | Buy |
+27,115
| New | +$3.27M | 0.24% | 178 |
|
|
2015
Q3 | – | Sell |
-20,676
| Closed | -$2.55M | – | 324 |
|
|
2015
Q2 | $2.55M | Sell |
20,676
-20,292
| -50% | -$2.56M | 0.16% | 235 |
|
|
2015
Q1 | $4.83M | Sell |
40,968
-749
| -2% | -$89.7K | 0.3% | 137 |
|
|
2014
Q4 | $4.96M | Buy |
41,717
+45
| +0.1% | +$5.07K | 0.31% | 125 |
|
|
2014
Q3 | $4.68M | Buy |
+41,672
| New | +$3.97M | 0.29% | 104 |
|
|
2014
Q2 | – | Sell |
-21,316
| Closed | -$1.51M | – | 305 |
|
|
2014
Q1 | $1.51M | Sell |
21,316
-5,280
| -20% | -$418K | 0.12% | 253 |
|
|
2013
Q4 | $1.98M | Sell |
26,596
-3,962
| -13% | -$276K | 0.15% | 210 |
|
|
2013
Q3 | $2.32M | Buy |
30,558
+7,235
| +31% | +$576K | 0.19% | 186 |
|
|
2013
Q2 | $1.87M | Buy |
+23,323
| New | +$1.72M | 0.17% | 192 |
|
Other funds holding VRTX
Nicholas Investment Partners's VRTX Position: Q1 2025 in Review
Nicholas Investment Partners sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 1,218 shares — an estimated $490K sold.
Nicholas Investment Partners first reported a position in VRTX in Q2 2013 and held it in 30 quarters. The position peaked at $33M in Q3 2023. 1,613 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.
- Nicholas Investment Partners reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
- Nicholas Investment Partners sold 1,218 Vertex Pharmaceuticals shares in Q1 2025, an estimated $490K.
- Nicholas Investment Partners first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 30 quarters.
- Nicholas Investment Partners's Vertex Pharmaceuticals position peaked at $33M in Q3 2023.
- 1,613 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.
Based on Nicholas Investment Partners's 13F filing for Q1 2025, filed 15 May 2025.